X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
GSK Pharma Fact Sheet, GSK Pharma Financial Results - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK Pharma Fact Sheet   (GLXO)

Here is the latest financial fact sheet of GSK Pharma. For more details, see the GSK Pharma quarterly results and GSK Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.

GSK PHARMA Price History

Price Rs 2,537.6
Mkt Cap Rs m 214,935
Vol '000 5.8
P/E X 63.8
P/CF X 53.7
EPS (TTM) Rs 39.8
% ch % -0.4
No. of shares m 84.70
% ch week % -0.5
% ch 1-mth % 3.2
% ch 12-mth % -25.0
52 week H/L Rs 3,430.0/2,309.1
(As on Jul 21, 2017 (Close))
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

GSK PHARMA Financials

No. of Mths
Year Ending
12
Dec-11
12
Dec-12
12
Dec-13
15
Mar-15
12
Mar-16
5-Yr Chart
Click to enlarge
GSK PHARMA EQUITY SHARE DATA
High Rs2,4752,3383,0023,5503,850 
Low Rs1,8301,9162,0052,3522,966 
Sales per share (Unadj.) Rs285.1312.9302.6396.5332.3 
Earnings per share (Unadj.) Rs50.666.356.955.744.3 
Diluted earnings per shareRs50.666.356.955.744.3 
Cash flow per share (Unadj.) Rs53.068.459.258.747.2 
Dividends per share (Unadj.) Rs45.0050.0050.0062.5050.00 
Adj. dividends per shareRs45.0050.0050.0062.5050.00 
Dividend yield (eoy) %2.12.42.02.11.5 
Book value per share (Unadj.) Rs228.5236.9234.9215.9202.7 
Adj. book value per shareRs228.5236.9234.9215.9202.7 
Shares outstanding (eoy) m84.7084.7084.7084.7084.70 
Bonus/Rights/Conversions  ----- 
Price / Sales ratio x7.66.88.37.410.3 
Avg P/E ratio x42.532.144.053.076.9 
P/CF ratio (eoy) x40.631.142.350.372.2 
Price / Book Value ratio x9.49.010.713.716.8 
Dividend payout %88.975.487.9112.2112.9 
Avg Mkt Cap Rs m182,317180,157212,038249,933288,643 
No. of employees `0005.14.75.04.74.6 
Total wages/salary Rs m2,7842,9553,6214,9304,434 
Avg. sales/employee Rs Th4,776.35,632.25,090.87,211.76,104.5 
Avg. wages/employee Rs Th550.7627.9719.31,058.6961.6 
Avg. net profit/employee Rs Th847.71,194.0956.91,012.7813.7 
GSK PHARMA INCOME DATA
Net Sales Rs m24,14426,50525,62733,58528,148 
Other income Rs m1,4561,7461,7701,9991,218 
Total revenues Rs m25,60028,25127,39735,58429,366 
Gross profit Rs m8,0248,2615,2826,2834,774 
Depreciation Rs m204178199254248 
Interest Rs m33000 
Profit before tax Rs m9,2739,8266,8538,0285,744 
Minority Interest Rs m00000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m-3,154-1,482262-51926 
Tax Rs m1,8342,7252,2982,7932,018 
Profit after tax Rs m4,2855,6194,8174,7163,752 
Gross profit margin %33.231.220.618.717.0 
Effective tax rate %19.827.733.534.835.1 
Net profit margin %17.721.218.814.013.3 
GSK PHARMA BALANCE SHEET DATA
Current assets Rs m26,05126,46726,23925,87021,462 
Current liabilities Rs m8,5968,3648,88911,06510,536 
Net working cap to sales %72.368.367.744.138.8 
Current ratio x3.03.23.02.32.0 
Inventory Days Days5039494168 
Debtors Days Days1316141116 
Net fixed assets Rs m1,1531,3321,6202,3834,717 
Share capital Rs m847847847847847 
"Free" reserves Rs m18,49319,20419,03317,65316,308 
Net worth Rs m19,35720,06819,89718,29017,171 
Long term debt Rs m4641362616 
Total assets Rs m29,68130,01731,29532,36430,620 
Interest coverage x3,092.03,276.3NMNMNM 
Debt to equity ratio x00000 
Sales to assets ratio x0.80.90.81.00.9 
Return on assets %14.418.715.414.612.3 
Return on equity %22.128.024.225.821.9 
Return on capital %31.641.535.741.033.6 
Exports to sales %1.50.70.40.20 
Imports to sales %7.88.112.312.915.1 
Exports (fob) Rs m36519695634 
Imports (cif) Rs m1,8732,1523,1594,3344,237 
Fx inflow Rs m799715625699519 
Fx outflow Rs m3,6424,1415,3807,6808,320 
Net fx Rs m-2,843-3,426-4,755-6,981-7,801 
GSK PHARMA CASH FLOW
From Operations Rs m 3,354 3,136 2,813 3,409 1,386 
From Investments Rs m 3,580 -1,097 1,890 1,776 5,010 
From Financial Activity Rs m -3,948 -4,406 -4,941 -4,970 -6,383 
Net Cashflow Rs m 2,986 -2,367 -239 215 12 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 0.0%
Foreign collaborators 50.7%
Indian inst/Mut Fund 10.2%
FIIs 23.8%
ADR/GDR 0.0%
Free float 15.4%
Shareholders 102,036
Pledged promoter(s) holding 0.0%
 

Company Information

REGD OFF Dr. Annie Besant Road, Worli, Mumbai - 400 030
E-MAIL ajay.a.nadkarni@gsk.com WEB www.gsk-india.com
TELEPHONE (022) 2495 9415 FAX (022) 2498 1526
SECTOR PHARMACEUTICALS GROUP M N C
TR AGENT Karvy Computershare, 17-24, Vithalrao Nagar, Madhapur, Hyderabad-81
AUDITOR Price Waterhouse & Co.
CHM: D. S. Parekh COMP SEC: A. A. Nadkarni (GM & Admin) YEAR OF INC: 1924 BSE CODE: 500660 FV (Rs): 10 DIV YIELD (%): 2.0

More Pharmaceuticals Company Fact Sheets:   AMAR REMEDIES  ALEMBIC LTD  SUN PHARMA  DISHMAN PHARMA  AJANTA PHARMA  

Compare GSK PHARMA With:   AMAR REMEDIES  ALEMBIC LTD  SUN PHARMA  DISHMAN PHARMA  AJANTA PHARMA  

Compare GSK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Stronger Euro Drags European Markets(RoundUp)

The strength of the euro does appear to be acting as a bit of a headwind for European stocks as they look to close the week sharply lower in contrast to the performance of UK and US stocks this week.

Views on news

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

More Views on News

Most Popular

Post Demonetisation Real Estate Sales Have Collapsed, But Prices Haven't(Vivek Kaul's Diary)

Jul 11, 2017

While sales have fallen dramatically, net net home prices continue to hold on.

Ride the Bull Wave with These Perfect Proxies to India's Growth Story(The 5 Minute Wrapup)

Jul 15, 2017

The secret of spotting multibaggers before they become a hit.

The New Pharma Rally Starts NOW(Daily Profit Hunter)

Jul 12, 2017

The most hated sector is offering the best trading opportunity. Are you ready?

All You Need To Know To e-File Your Income Tax Returns(Outside View)

Jul 12, 2017

The Income Tax return filing deadline is drawing near; if you have not already filed your taxes, here's how to do it.

The Impact of GST On Banking transactions, Insurance, and Investments(Outside View)

Jul 11, 2017

PersonalFN explains how GST impacts your insurance premiums, investments, and banking transactions.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GSK PHARMA

GSK PHARMA - SANOFI INDIA COMPARISON

COMPARE GSK PHARMA WITH

MARKET STATS